US stock futures advanced across the board ahead of Monday's trading session. As of writing, Dow futures were up 0.30%, S&P 500 futures gained 0.77%, and Nasdaq futures surged 1.42%.
European markets showed a mixed picture. The German DAX index was down 0.36%, while the UK's FTSE 100 edged up 0.17%. The French CAC 40 dipped 0.06%, and the Euro Stoxx 50 rose 0.07%.
In commodities, WTI crude oil climbed 1.13% to $91.56 per barrel, and Brent crude increased 1.21% to $94.22 per barrel.
Market Overview
Wall Street is bracing for a week of significant tests, with renewed Middle East tensions, the historic SpaceX IPO, and a fresh wave of inflation data on the horizon. Following last Friday's market-wide repricing, which saw investors betting on a Federal Reserve rate hike this year, the mood is cautious as the new week begins.
The spotlight will be firmly on Friday when Elon Musk's SpaceX is set to go public in what is expected to be the largest IPO in history. After last week's surprisingly strong non-farm payrolls report, investors face another round of critical economic data. Inflation will be the central theme, with US May CPI and PPI figures scheduled for release on Wednesday and Thursday, respectively.
Regarding the Middle East situation, the recent direct conflict between Iran and Israel has introduced further obstacles to a potential US-Iran agreement, raising concerns that inflation expectations may remain elevated.
On the corporate earnings front, Oracle (ORCL) will lead the week with its fourth-quarter report on Wednesday, serving as another key indicator for assessing the state of the AI and cloud computing trade. Additionally, Adobe (ADBE) is set to report its earnings on Thursday.
Iran Halts Military Action Against Israel
Iranian media reported on June 8th that the Iranian armed forces announced a halt to military actions against Israel. This follows mutual strikes between Iran and Israel on the 7th and 8th. A statement indicated that Iran has delivered a severe response to Israel, from which Israel should draw lessons. However, the statement warned that if Israel continues its aggressive and criminal actions in places like southern Lebanon, Iran will implement more severe and destructive measures.
Soaring Inflation Expectations Crush Rate Cut Bets
The US Treasury market is under significant pressure as traders widely anticipate that upcoming inflation data will show the most substantial consumer price increase in years, reinforcing expectations for further Fed tightening. Swap contracts linked to the US May CPI data due Wednesday suggest the market expects an annual rate of around 4.3%, potentially the highest reading since 2023, against a backdrop of elevated energy prices due to the US-Iran standoff.
The prospect of a lasting ceasefire remains unclear, suggesting energy prices could stay high, thereby increasing inflationary pressures. Concurrently, the resilient US economy is diminishing bond market hopes for monetary easing. As of writing, the 10-year Treasury yield was at 4.54%, while the more policy-sensitive 2-year yield stood at 4.149%.
All Eyes on Warsh's Debut for Rate Hike Clues
With the US labor market remaining strong and inflation showing no signs of abating, experts on Wall Street and in Washington predict the upcoming Federal Reserve policy meeting will send a clear signal that the next likely policy move is a rate hike.
This meeting will be the first chaired by new Fed Chair Kevin Warsh. Economists generally believe the June meeting will likely keep rates unchanged, but the market will focus on three key clues to judge if the Fed is paving the way for a hike later this year: the potential removal of the easing bias language from last December's policy statement, a key way for Warsh to demonstrate policy independence; a hawkish shift in the dot plot; and a renewed focus on inflation risks in the risk assessment. Beyond policy, markets are also watching whether Warsh will immediately adjust the Fed's external communication style.
OPEC+ Symbolically Raises Output Quota
Seven OPEC+ countries, led by Saudi Arabia and Russia, announced after a video conference on Sunday that they would raise their collective production target by 188,000 barrels per day next month, continuing the process of restoring output previously halted due to market oversupply. However, this action remains largely theoretical for now.
The reality of blocked exports through the Persian Gulf means most member states cannot practically implement this increase. The plan will only become operational once this key shipping lane reopens and buyers rush to purchase crude to replenish depleted global oil inventories.
Individual Stock Movements
US chip stocks rebounded in pre-market trading on Monday, recovering from Friday's broad sell-off. As of writing, Marvell Technology (MRVL) was up nearly 9%, Micron Technology (MU) gained almost 6%, Broadcom (AVGO) and Advanced Micro Devices (AMD) rose nearly 3%, while Intel (INTC) and NVIDIA (NVDA) were up over 2%. Additionally, ASML Holding NV (ASML) climbed over 4%, and Taiwan Semiconductor Manufacturing (TSM) advanced nearly 3%.
US commercial space stocks also moved higher pre-market. Momentus Inc. (MNTS) and Intuitive Machines (LUNR) were up nearly 5%, MDA Space Ltd. (MDA) gained over 4%, Redwire Corp. (RDW), Rocket Lab USA, Inc. (RKLB), and Voyager Technologies, Inc. (VOYG) rose more than 3%, York Space Systems (YSS) was up nearly 3%, and Firefly Aerospace Inc. (FLY) and AST SpaceMobile, Inc. (ASTS) increased over 2%.
Apple's WWDC 2026 Preview
Apple's 2026 Worldwide Developers Conference (WWDC) is set to begin at 1 AM Beijing Time on June 9th at its Cupertino headquarters. This event is not only Apple's most important annual software showcase but also the last one to be publicly hosted by CEO Tim Cook before his departure. Facing an awkward track record of missed promises in the AI field over the past two years, Apple urgently needs a powerful launch event to prove to Wall Street and consumers that it can still lead the generative AI wave.
Beyond the highly anticipated updates to iOS 27, iPadOS 27, macOS 27, and a complete overhaul of Siri, analysts suggest three key signals to watch at this year's developer conference: whether it can reignite the device replacement cycle—if new AI capabilities are again tied to new hardware, revenue forecasts for the next two to three years could be revised upward; whether AI can create new monetization models—if Apple Intelligence and AI Agents can generate new platform revenue, the market's valuation framework for Apple (AAPL) could shift again; and whether Apple can build new moats—demonstrating its ability to define platform rules in the AI era.
NVIDIA and SK Hynix Announce AI Memory Partnership
NVIDIA (NVDA) and SK Hynix announced a multi-year technology partnership to jointly develop next-generation memory for global AI factories and apply AI technology to semiconductor chip design and manufacturing. Under the agreement, SK Hynix will co-develop specialized memory for NVIDIA's Vera Rubin AI supercomputer, Vera CPU, RTX Spark PC, and Jetson Thor robotic computing platforms, gaining entry into new markets NVIDIA is pioneering, such as AI infrastructure, personal AI, and physical AI.
In semiconductor manufacturing, SK Hynix will utilize NVIDIA's CUDA-X libraries and PhysicsNeMo framework to accelerate chip simulation and lithography computational workflows. It will also leverage NVIDIA Omniverse and cuOpt to build digital twins of wafer fabs, advancing autonomous factory operations.
Nurix Therapeutics Soars on Major Roche Deal
Pharmaceutical giant Roche Holding Ltd (RHHBY) has agreed to pay up to $2.3 billion to US biopharma company Nurix Therapeutics (NRIX) for rights related to an experimental blood cancer drug, bexobrutideg. Bexobrutideg is a novel oral BTK degrader developed by Nurix. Roche and Nurix stated that the drug may have advantages over current BTK inhibitors as it could overcome resistance mutations that develop during treatment.
This collaboration further reflects Roche's strategy to strengthen its oncology portfolio. As several blockbuster drugs mature, Roche is seeking new growth drivers. Boosted by this news, Nurix's stock surged over 70% in pre-market trading on Monday, though gains had moderated to about 11% as of writing.
Incyte's Major Acquisition Under New Leadership
According to sources familiar with the matter, as mid-sized drugmakers continue to seek acquisitions to bolster their pipelines, Incyte (INCY) is nearing a deal to acquire private company Star Therapeutics for up to $2 billion. The biotech firm is expected to pay approximately $1.25 billion upfront in cash, with an additional $750 million tied to future performance milestones.
The acquisition will give Incyte access to Star's leading experimental treatment for von Willebrand disease, the most common inherited bleeding disorder. The therapy, named VGA039, is in late-stage clinical trials and has received Fast Track designation from the US FDA. As of writing, Incyte's stock was up over 2% in pre-market trading.
Eli Lilly Targets New Frontier in Weight-Loss Drugs
Eli Lilly (LLY) stated that a new analysis of late-stage clinical trial data shows its experimental weight-loss therapy, Foundayo, enabled significant weight loss in overweight or obese women, with effectiveness unaffected by menopausal transition status (pre-, peri-, or post-menopausal). Menopause is a biological transition marked by declining reproductive hormones, often leading to changes in metabolism and body composition.
Many women experience increased fat accumulation (especially abdominal) during this period and find weight loss more difficult. This data could help Lilly expand the potential market for its obesity portfolio by demonstrating the drug's efficacy in a large and often overlooked patient population. As of writing, Eli Lilly's stock was up nearly 2% in pre-market trading.
Upcoming Economic Data and Events
Beijing Time 23:00: US May New York Fed 1-Year Inflation Expectations
Earnings Preview for Tuesday Pre-Market
EHang Holdings Ltd (EH)
Comments